ClinicalTrials.Veeva

Menu

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Bausch + Lomb logo

Bausch + Lomb

Status and phase

Completed
Phase 2
Phase 1

Conditions

Glaucoma
Open Angle or Ocular Hypertension

Treatments

Drug: brinzolamide 1% ophthalmic suspension
Drug: Azopt 1%

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Full description

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.

Enrollment

637 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and females 18 years of age or older,
  • diagnosed with primary open-angle glaucoma or ocular hypertension.

Exclusion criteria

  • Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,
  • ocular hypertension.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

637 participants in 2 patient groups

Azopt 1% ophthalmic suspension
Active Comparator group
Description:
Ophthalmic suspension
Treatment:
Drug: Azopt 1%
Brinzolamide 1% ophthalmic suspension
Experimental group
Description:
ophthalmic suspension
Treatment:
Drug: brinzolamide 1% ophthalmic suspension

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems